Outlier Ambition.Transformational Tech.Compounding Execution.

Venture capital produces two returns: financial and strategic. Traditional funds are built to optimise the first, and they do it well. They pool capital from many backers, so one mandate has to suit them all.

Some backers want both returns. A government, corporation, industry body or research institute is investing for a financial return and for something specific in its own domain: a region, a sector, a technology. They want control of that mandate but not the job of running a fund, so they partner with us on a sole-LP fund built to their brief.

For builders that creates a second kind of backer. If you are spinning technology out of research, building hardware or biology, or selling into agriculture or defence, an industry-aligned backer brings distribution, domain expertise and a credible acquirer.

The two models are not rivals. They have different ambitions, and many strong companies need both.

Not necessarily, but it depends what they meant.

Traditional venture seeks a financial return inside a seven to ten year fund life, which pushes it toward capital-light software and leaves hardware, deep tech and slower-adoption sectors underserved. If you were declined on capital intensity or time to revenue, that is a statement about their fund.

If you were declined because the market is small or the team is wrong, we will reach the same view.

Our capital comes from institutions prepared to wait, but we still need companies capable of an outlier result.

Six. Each one exists because an institution has a stake in the technology getting built.

Agrifood. Industry bodies and agribusinesses invest to lift productivity from constrained land and water, and to protect their sector's competitiveness.

Climate. Governments carry emissions targets. Utilities and heavy industry carry transition risk. Both need generation, storage, grid and industrial decarbonisation to work.

Health. Insurers, health services and research institutes invest against cost and workforce pressure that more spending will not fix.

Defence. Governments invest in resilience, intelligence and capability they need to own rather than import.

AI and Autonomy. Corporations invest where labour scarcity meets productivity, and to run R&D outside their own walls.

Frontier. Universities and research institutes back technologies that do not yet fit a category, where the science is ahead of the market.

None of them invests for financial return alone. That is why there is real demand behind the money.

Yes: the filter is whether the technology is transformative and critical to the problem our backer needs solved, not its category. Sometimes that is software. Often it is hardware, biology or the physical systems software runs on.

We can hold the slow, capital-intensive kind. A pooled fund struggles because a ten year life has to close whatever stage the science is at. Our funds are built around a specific institutional problem, so the horizon and cheque shape follow what solving it takes.

A government building sovereign capability needs satellites, materials and manufacturing. An industry body renewing its sector needs machinery, sensors and biology. A research institute needs its lab science commercialised.

Physical technology gains more from an industry-aligned backer than pure software does. A sensor, a device or a biological product needs a trial site, a regulatory pathway and a first buyer, which is what our backers can open.

Primarily early stage, from pre-seed through Series A and beyond, with each fund's mandate setting its own focus.

And yes to both parts of the second question. We invest pre-revenue as a matter of course, and in deep tech and life sciences we invest before there is a product in any commercial sense. Many of our 600+ portfolio companies were first backed at pre-seed or seed.

What we cannot fund is science without a path. Before we can act we need three things: a defined technical milestone you are working toward, the team that will actually hit it, and a credible account of what the next investor will need to see.

As a marker of the earliest we will genuinely look: a working prototype or a lab-validated result, a full-time founding team, and at least one named design partner or first customer, paid or unpaid. Short of that we are not the wrong investor, we are the right conversation in nine months.

We invest from mandates rather than from a fixed geography. Each mandate has a scope agreed with the institution that anchors it, and that scope is usually set by sector.

Some are deliberately tight, such as a state fund built to grow companies in that state. A growing number are global, and we run them from nine offices across the Americas, Europe and Asia Pacific.

Much of our capital still sits in Australia and New Zealand, where we started. Our newer mandates increasingly do not.

The best route in is a warm introduction. Someone who has worked with us, a builder we have backed, one of our backers, or anyone who knows the investment team, carries something a form cannot: their judgement that you are worth half an hour. We read those first, and we read them differently.

If you do not have that route, use the pitch form. It goes straight to the venture team, asks the same questions of everyone, and means nothing is lost in an inbox. Plenty of our companies arrived that way.

Either way the first conversation is 30 minutes and needs no deck. Work out who in your network touches ours before you send anything cold. It is usually a shorter path than it looks.

Every submission is read by the venture team and assessed against our live mandates.

We receive a high volume of applications and we cannot respond to all of them. We reach out directly to the companies we shortlist for further discussion, so no reply does not mean no read.

If we do come back to you, the first step is that 30 minute conversation. After it we will tell you where you stand: no, with the reason; not yet, with what would change our answer; or yes to diligence, which is a structured process covering market, technology, team, commercial, financial, legal and ESG, run by a named lead who stays with you throughout and ends in a written memo to our Investment Committee.

Four things.

The problem, and who in the industry actually has it. Why now: what changed in the technology, the regulation or the market that makes this possible today and not three years ago. Why you: what your team knows that others working on this do not. And what the next twelve months buys: the milestone this round reaches, and what it proves.

Half an hour is enough for all four. If one is still forming, say so. That is more useful to us than a confident guess.

Artesian runs the investment process end to end: sourcing, diligence, the memo and the recommendation.

Where a fund has a single institutional backer, that backer is a full partner in it. They sit on the Investment Committee and are engaged through diligence. So a builder pitching one of those mandates is, in effect, in a room that includes the corporate, government or university anchoring the fund.

We tell you which mandate you are being considered for, and who anchors it, before diligence begins. For most builders this is the point of coming to us: the strategic party who could become your first customer, your route to market or your acquirer is in the room from the start, not introduced years later.

Sometimes, and you will hear it from us before you find out any other way.

Within a single mandate we do not back head-to-head competitors. If we have already funded a direct competitor from the fund considering you, we will say so in the first conversation and stop there, rather than take a meeting for the information.

Across mandates we may hold companies in the same broad sector. Agrifood, for example, is a wide field, and two companies can both work in soil analytics without competing for the same customer. Where two mandates hold companies that genuinely overlap, that is disclosed and managed, not denied. We run a documented conflicts and allocation policy covering disclosure, recusal and information barriers, reviewed at every Investment Committee.

Generally not to hear a pitch, and the reasoning is worth more than the convention.

We review a large volume of companies across six domains, often several in the same corner of the same market. Signing an NDA to take a first meeting would make it impossible to look at the next company honestly. Almost no venture fund does it, and we would rather explain that than hide behind it.

What we do instead: your material is treated as confidential in practice, access-controlled to the named team on your file. We tell you which mandate is considering you and who anchors it before diligence begins, because where a fund has an institutional backer that backer is engaged through diligence. And once we commit to diligence we will sign a mutual NDA covering the detailed technical, financial and customer material that phase requires.

If your core asset is a trade secret rather than a patent, say so on the first call and we will structure what you share around it.

Artesian often leads rounds, and we are explicit about where we stop.

Our typical position is the anchor cheque: the visible early commitment that signals conviction and helps you assemble the rest of the round. We are willing to be first in, and we build the syndicate around us, bringing in co-investors chosen for domain expertise rather than convenience.

Where we hold a line is on consecutive rounds. A fund that keeps leading its own follow-ons manufactures circular valuations and, eventually, a mark nobody outside believes. So we may lead any early round, and we will not lead consecutive follow-ons without meaningful external participation. That is not caution about you. A round led and priced by an independent third party is the only honest mark your company can carry, and you will need that mark long before you need an exit.

Practically: approach us early rather than last. We are most useful at the front of a round.

Artesian does invest again, and reserves are designed into every fund rather than granted case by case.

Our funds diversify where the risk is still unknowable and concentrate where the evidence has arrived: a wide set of disciplined early positions, and a substantial reserve, generally 50 to 60% of the fund depending on the mandate, to back the companies whose evidence compounds. Reserves are deployed on evidence, not on a schedule.

Two further sources of capital sit behind the fund and matter more to you than the reserve does. Our mandates run co-investment partnerships that bring institutional and strategic capital directly into company rounds, which is what carries capital-intensive growth rounds rather than the fund's own balance sheet. And at platform level we build later-stage vehicles that take concentrated positions in the strongest companies across the portfolios we manage.

A single fund does cap its exposure to any one company, generally 10 to 20% depending on the mandate. Past that point our job is to bring other capital to you rather than write the cheque ourselves.

Our funds are anchored by institutions already operating in your sector. They are not passive money. They run pilots, they buy, and some have acquired portfolio companies.

So you get a first customer rather than an introduction to one, and a way into government, health systems and large industrials that is largely closed without a sponsor.

You also diversify your capital source. Venture money all comes from the same pool and dries up together. Ours comes from government budgets, corporate balance sheets and industry levies, which move on a different cycle.